Last day of trading in warrants of series 2019/2021 is February 4, 2021 - Regulatory information

01-02-2021   Regulatory press release

February 4, 2021 is the last day of trading in warrants of series 2019/2021. The subscription period for warrants of series 2019/2021 runs until and including February 8, 2021. Each warrant gives the right to subscribe for one (1) new B share in ADDvise. The subscription price for the warrants is SEK 0.65 per share of series B.

Summarized terms for the warrants of series 2019/2021

Subscription period: January 25, 2021 – February 8, 2021

Size of issue: 43,042,288 warrants of series 2019/2021. Upon full exercise, 43,042,288 shares will be issued and ADDvise receives approximately SEK 28 million before issue costs

Subscription price: SEK 0.65 per series B share

Last day of trading in warrants of series 2019/2021: February 4, 2021

Note that warrants that are not sold no later than February 4, 2021, or alternatively exercised by February 8, 2021, expire worthless. In order for your warrants of series 2019/2021 not to expire, you must subscribe for shares or sell your warrants.

Letter to warrant holders of series 2019/2021 is available at the Company's website,, and Mangold’s website, Full terms for the warrants were included as part of the investment memorandum that was published on January 16, 2019. The investment memorandum and full terms and conditions for the warrants are also available at the above websites.How to exercise the warrants

Nominee-registered warrants (custody)

Subscription and payment through the exercise of the warrant shall take place in accordance with instructions from the respective nominee. Please contact your trustee for further information.

Directly registered warrants (VP ​​account):

No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at Bolagsverket.

The application form with instructions for payment is available on the Company's website,, and on the issue institute Mangold Fondkommission AB's website,


Mangold Fondkommission is the financial adviser and Advokatfirman Schjødt is the legal advisor to ADDvise regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595


For further information:

Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23


About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected


The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million


ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…